Elsevier

Clinical Breast Cancer

Volume 8, Supplement 4, December 2008, Pages S171-S178
Clinical Breast Cancer

Basal and Triple-Negative Breast Cancers: Impact on Clinical Decision-Making and Novel Therapeutic Options

https://doi.org/10.3816/CBC.2008.s.014Get rights and content

Abstract

Since the first application of gene expression profiling to breast cancer almost a decade ago, the molecular subtyping of breast cancer has advanced rapidly from a novel concept to a clinically valuable prognostic, and possibly predictive, classification. This review summarizes the definition of the basal and related triplenegative subtypes of breast cancer, their clinical associations, and effect on outcome and treatment decision-making. Particular emphasis is placed on the clinical implications of basal breast cancer and potential therapeutic options available to oncologists.

References (72)

  • S Modi et al.

    A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer

    Clin Breast Cancer

    (2006)
  • CM Perou et al.

    Molecular portraits of human breast tumours

    Nature

    (2000)
  • T Sorlie et al.

    Repeated observation of breast tumor subtypes in independent gene expression data sets

    Proc Natl Acad Sci U S A

    (2003)
  • T Sørlie et al.

    Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

    Proc Natl Acad Sci U S A

    (2001)
  • LJ van't Veer et al.

    Gene expression profiling predicts clinical outcome of breast cancer

    Nature

    (2002)
  • TO Nielsen et al.

    Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

    Clin Cancer Res

    (2004)
  • LA Carey et al.

    Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

    JAMA

    (2006)
  • S Paik et al.

    A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

    N Engl J Med

    (2004)
  • M Buyse et al.

    Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

    J Natl Cancer Inst

    (2006)
  • LA Carey et al.

    The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

    Clin Cancer Res

    (2007)
  • EA Rakha et al.

    Prognostic markers in triple-negative breast cancer

    Cancer

    (2007)
  • MC Cheang et al.

    Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

    Clin Cancer Res

    (2008)
  • PL Nguyen et al.

    Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy [published erratum appears in: J Clin Oncol 2008; 26:3110]

    J Clin Oncol

    (2008)
  • F Bertucci et al.

    How basal are triple-negative breast cancers?

    Int J Cancer

    (2008)
  • F Bertucci et al.

    Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers

    Cancer Res

    (2006)
  • B Weigelt et al.

    Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

    Breast Cancer Res Treat

    (2008)
  • MR Carter et al.

    Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases

    Am J Surg Pathol

    (2006)
  • SM Rodríguez-Pinilla et al.

    Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas

    Clin Cancer Res

    (2006)
  • H Li et al.

    Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors

    Cancer Res

    (2007)
  • PM Carpenter et al.

    Laminin 5 expression in metaplastic breast carcinomas

    Am J Surg Pathol

    (2008)
  • JV Moyano et al.

    AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

    J Clin Invest

    (2006)
  • JB Arnes et al.

    Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer

    Clin Cancer Res

    (2005)
  • SE Elsheikh et al.

    Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype

    Br J Cancer

    (2008)
  • E Charafe-Jauffret et al.

    Moesin expression is a marker of basal breast carcinomas

    Int J Cancer

    (2007)
  • S Lu et al.

    Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance

    Clin Cancer Res

    (2008)
  • JB Arnes et al.

    Expression of EGFR in relation to BRCA1 status, basal-like markers and prognosis in breast cancer

    J Clin Pathol

    (2008)

    • Cited by (0)

    Dr. Voduc has no relevant relationships to disclose.

    Dr. Nielsen has received research support from sanofi-aventis Canada.

    This article includes discussion of investigational and/or unlabeled uses of drugs, including lapatinib, carboplatin, sunitinib, dasatinib, erlotinib with or without chemotherapy, imatinib with or without vinorelbine, cetuximab with or without carboplatin, or bevacizumab plus capecitabine for advanced or metastatic breast cancer; carboplatin plus a PARP inhibitor for the treatment of breast or ovarian cancer; paclitaxel plus fluorouracil, doxorubicin, and cyclophosphamide for the neoadjuvant treatment of patients with breast cancer, and bevacizumab plus chemotherapy for the adjuvant or neoadjuvant treatment of patients with breast cancer.

    View full text
    Copyright © 2008 Elsevier Inc. All rights reserved.